Heterophyllin B alleviates cognitive disorders in APP/PS1 model mice via the spleen-gut microbiota-brain axis.

BACKGROUND

Accumulating evidence implicates both the brain-spleen axis and the gut microbiota-brain axis in Alzheimer's disease (AD) pathogenesis. While our previous work demonstrated heterophyllin B (HB) rectifies splenic Th1/Th2 imbalance and ameliorates cognitive deficits in Aβ1-42-induced AD mice, its potential modulation of the vagus nerve-spleen circuit remains unexplored.

METHODS

Using 8-month-old male APP/PS1 mice with/without splenic denervation (SD), we systematically investigated HB's therapeutic mechanisms via the spleen-gut microbiota-brain axis. Cognitive function was assessed through novel object recognition (ORT) and object location memory (OLT) tests. Immunofluorescence (IF) and enzyme-linked immunosorbent assay (ELISA) were employed to analyze Aβ plaques, phosphorylated tau (p-Tau) levels, and associated neuroinflammatory responses. Flow cytometry was utilized to examine the subtypes of splenic lymphocytes. Hematoxylin and eosin (H&E) staining, along with immunohistochemical (IHC) experiments, was conducted to evaluate the protective effects of HB on the intestinal barrier. Gut microbiota composition was analyzed using 16S rRNA sequencing.

RESULTS

HB administration significantly improved cognitive performance (ORT discrimination index: +28.7 %; OLT discrimination index: +26.6 %), reduced brain and serum Aβ1-42 and p-Tau levels, downregulated the Th1/Th2 ratio in the spleen, and alleviated intestinal permeability and neuroinflammation, which were abolished in SD APP/PS1 mice. Gut microbiota shifts showed HB-induced enrichment of cognition-associated Dubosiella and Muribaculaceae, with concurrent suppression of pathogenic Lachnospiraceae_NK4A136 and ASF356.

CONCLUSION

This study provides first evidence that HB ameliorates AD pathology through vagus nerve-dependent regulation of the spleen-gut microbiota-brain axis, establishing its multimodal therapeutic potential for neural-immune-gut circuit modulation in neurodegenerative diseases.